FTC Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, a commission may be earned at no additional cost to you. Editorial content is not influenced by affiliate relationships. MedFoundationNC.org is an independent publication — not a medical practice, hospital, or healthcare provider.
By MedFoundationNC.org Editorial Team | Last Updated: April 9, 2026
You started a GLP-1 injection six or eight months ago. The first few months were remarkable — your appetite dropped, the scale moved, and you felt like you'd finally found something that worked. Then the progress slowed. Maybe the scale hasn't moved in weeks. Maybe the appetite suppression that felt so strong at the beginning has faded. Maybe you're still losing, but the side effects have gotten worse and you're questioning whether the tradeoff is worth it. You're not imagining things, and you're not alone.
Published data from clinical trials and real-world adherence studies confirms that approximately half of people who start GLP-1 injection therapy discontinue treatment — some temporarily, some permanently. The reasons vary, but the most common patterns are predictable: weight loss plateaus, side effect fatigue, cost pressure, injection burden, and supply disruptions. This article covers what's actually happening when your GLP-1 injection seems to stop working and what your current options look like as of April 2026.
Why Weight Loss Plateaus on GLP-1 Injections
Weight loss on GLP-1 medications doesn't follow a straight line. The published clinical trial data shows the fastest weight loss typically occurs in the first 20 to 30 weeks of treatment, with the rate gradually slowing as you approach a new equilibrium. This isn't the medication failing — it's your body adapting to a new metabolic baseline.
Several factors contribute to the slowdown. Metabolic adaptation is the most fundamental: as you lose weight, your body requires fewer calories to maintain its reduced mass. The same caloric deficit that produced rapid early weight loss produces smaller losses — or maintenance — at a lower body weight. Behavioral drift also plays a role. The dramatic appetite suppression of early treatment can lead people to relax dietary habits or exercise routines, which offsets some of the medication's effect. Dose tolerance, while not formally established for all GLP-1 drugs, is a concern many patients and clinicians report anecdotally — the feeling that the medication's appetite-suppressing effect weakens over time at the same dose.
If you've hit a plateau, the first conversation should be with your prescribing provider about whether dose optimization is possible. If you're not yet on the maximum dose, increasing may restart progress. If you're already at maximum dose and the plateau has lasted more than eight to twelve weeks, it may be time to evaluate alternatives.
When Side Effects Become the Problem
Gastrointestinal side effects — nausea, vomiting, constipation, diarrhea — are the most commonly reported reasons for discontinuing GLP-1 injection therapy. According to published trial data, discontinuation rates due to adverse events range from approximately 4% to 10% depending on the specific medication and dose. For some people, the side effects are manageable early on but become cumulative over months of treatment.
Injection site reactions are another friction point. Published prescribing information for injectable GLP-1 medications lists pain, redness, and itching at the injection site as common adverse events. While most reactions are mild, repeated injections at the same sites can cause tissue changes over time. Rotating injection sites helps but doesn't eliminate the issue entirely.
If side effects are driving your decision to stop, understand that switching to a different GLP-1 medication — rather than stopping entirely — may resolve the problem. Different GLP-1 drugs have different side effect profiles, and individual tolerance varies. As of April 2026, the oral GLP-1 options eliminate injection site reactions entirely and may offer a different gastrointestinal side effect experience. For the complete side effect profile of the newest oral option, our Foundayo side effects and safety guide provides the published clinical data.
The Cost and Access Problem
Even when the medication is working, cost can force discontinuation. Injectable GLP-1 medications carry higher price points than the newer oral alternatives, and insurance coverage remains unpredictable. Published analyses show that over 16 million Americans with private insurance lack coverage for GLP-1 weight loss medications as of 2026. For those paying out of pocket, monthly costs for injectable medications can reach $299 to $449 depending on the specific drug and dose.
Supply disruptions have also plagued the injectable GLP-1 market. Demand has consistently outpaced manufacturing capacity, leading to pharmacy shortages that force patients into treatment gaps — which can trigger weight regain and require dose re-escalation when supply returns.
The oral GLP-1 pills entering the market in 2026 may help on both fronts. Pills are generally less expensive to manufacture and distribute than injectable biologics, and they don't require the cold-chain logistics that complicate injectable supply chains. As of April 2026, both Foundayo and the Wegovy pill are priced starting at $149 per month for cash-pay customers at their lowest doses — meaningfully below the typical cash price for their injectable counterparts. For a full pricing breakdown, see our Foundayo cost and access guide.
Switching from Injections to an Oral GLP-1 Pill
One of the most significant developments in the GLP-1 space in 2026 is published clinical data supporting the injectable-to-oral transition. Eli Lilly published Phase 3 results from a first-of-its-kind trial showing that patients who initially lost weight on injectable GLP-1 therapy were able to maintain that weight loss after switching to oral Foundayo. This wasn't previously established — and it creates a new treatment pathway that many physicians are beginning to incorporate into long-term care plans.
The model works like this: use the more aggressive injectable medication to achieve your initial weight loss target, then transition to a daily oral pill for long-term maintenance. The benefits are practical — lower cost, no more injections, no cold storage, simpler routine — and the published data suggests it can be done without sacrificing the weight you've already lost.
If you're considering this transition, discuss it with your prescribing provider. The switch involves starting the oral medication at its lowest dose and titrating up, which means a period of dose escalation even if you were previously on a high-dose injectable. Your provider will need to monitor your response during the transition period. For an understanding of how the dosing transition works, our guide to GLP-1 pills versus injections covers the titration schedules for both oral options.
Compounded GLP-1 Options as an Alternative
Some patients who discontinue FDA-approved injectable therapy turn to compounded GLP-1 formulations available through telehealth platforms. These programs typically offer compounded semaglutide or tirzepatide at lower monthly price points than FDA-approved branded medications. As of April 2026, published pricing from major telehealth GLP-1 platforms ranges from approximately $179 to $349 per month.
Compounded medications are not FDA-approved as finished products — they combine FDA-approved active ingredients in custom formulations. The regulatory environment for compounded GLP-1 products has tightened significantly, with the FDA increasing enforcement actions throughout 2025 and 2026. If you're evaluating this path, our MEDVi analysis, TrimRx evaluation, and Direct Meds review cover the verified facts, regulatory status, and consumer experiences for three of the most prominent platforms.
When Stopping GLP-1 Treatment Is the Decision
If you're considering stopping GLP-1 therapy entirely, the published data is clear about what to expect. Weight regain after discontinuation is well-documented across every GLP-1 medication studied. This doesn't mean stopping is the wrong decision — it means the decision should be informed, not impulsive.
Before stopping, have a direct conversation with your provider about what comes next. Behavioral strategies, dietary changes, and exercise programs can help mitigate regain, but they rarely fully replace the metabolic effects of the medication. If cost is the driver, explore whether an oral option at a lower price point could extend your treatment. If side effects are the driver, explore whether a different medication in the same class produces a more tolerable experience. If the medication genuinely isn't producing results at maximum dose after an adequate trial period, it may be appropriate to stop — but document your experience and discuss it with your provider, because the GLP-1 pipeline continues to expand with new mechanisms and formulations that may offer different results.
The GLP-1 treatment market in April 2026 looks fundamentally different from where it was even six months ago. If your injection isn't working the way it used to — or isn't working for your life — you have more options now than you've ever had. Start that conversation with your healthcare provider and explore what fits. Our comparison of Foundayo, Wegovy, and Zepbound can help you prepare for that discussion with the published data at hand.
Published April 9, 2026. MedFoundationNC.org Editorial Team.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Do not stop, start, or change any medication without consulting your healthcare provider. All clinical claims are attributed to published trial data, FDA labeling, or cited sources. Individual results vary. MedFoundationNC.org is an independent editorial publication — not a medical practice, hospital, or healthcare provider.